Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:06:22 EDT Fri 19 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:CADL from 2023-04-20 to 2024-04-19 - 25 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-04-11 09:00
U
U:CADL
News Release
200
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
2024-04-09 08:00
U
U:CADL
News Release
200
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
2024-04-04 08:00
U
U:CADL
News Release
200
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2024-03-28 16:05
U
U:CADL
News Release
200
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
2024-03-28 08:06
U
U:CADL
News Release
200
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
2024-03-05 16:30
U
U:CADL
News Release
200
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
2024-02-13 07:30
U
U:CADL
News Release
200
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
2024-02-05 08:00
U
U:CADL
News Release
200
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
2023-12-12 08:00
U
U:CADL
News Release
200
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
2023-11-28 09:00
U
U:CADL
News Release
200
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN ¢ „ ¢ Discovery Platform, and Key Clinical Readouts for CAN-2409
2023-11-09 08:00
U
U:CADL
News Release
200
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-04 08:00
U
U:CADL
News Release
200
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN ¢ „ ¢ Discovery Platform at SITC
2023-11-03 12:00
U
U:CADL
News Release
200
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2023-10-18 11:00
U
U:CADL
News Release
200
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
2023-09-27 09:41
U
U:CADL
News Release
200
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
2023-09-26 08:00
U
U:CADL
News Release
200
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
2023-09-06 08:00
U
U:CADL
News Release
200
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 08:00
U
U:CADL
News Release
200
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-02 08:00
U
U:CADL
News Release
200
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
2023-06-13 08:00
U
U:CADL
News Release
200
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
2023-06-08 08:00
U
U:CADL
News Release
200
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
2023-06-05 08:00
U
U:CADL
News Release
200
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-05-19 09:00
U
U:CADL
News Release
200
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
2023-05-11 08:00
U
U:CADL
News Release
200
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-02 08:00
U
U:CADL
News Release
200
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO